Lv61
2170 积分 2024-01-29 加入
Association of PD-L1 expression and clinical outcomes in ROS1-rearranged advanced non-small cell lung cancer treated with entrectinib
1个月前
已完结
Progressive metastatic infantile fibrosarcoma with multiple acquired mutations
3个月前
已关闭
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823)
3个月前
已关闭
Regulating Tumorigenicity and Cancer Metastasis through TRKA Signaling
4个月前
已完结
Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
4个月前
已完结
Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer
4个月前
已关闭
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial
4个月前
已完结
EXTH-80. PBI-200: IN VIVO EFFICACY OF A NOVEL, HIGHLY CNS-PENETRANT NEXT GENERATION TRK INHIBITOR
4个月前
已关闭
A phase II basket study of the oral TRK inhibitor LOXO–101 in adult subjects with NTRK fusion-positive tumors
4个月前
已关闭
2013P Repotrectinib in adult and pediatric patients with NTRK+ advanced solid tumors: Updated results from the TRIDENT-1 and CARE trials
4个月前
已关闭
皖公网安备34019202002308
